Portal de Periódicos da CAPES

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy

2017; Elsevier BV; Volume: 28; Issue: 11 Linguagem: Inglês

10.1093/annonc/mdx414

1569-8041

Caroline E. McCoach, Gideon M. Blumenthal, L. Zhang, Adrian Myers, Shenghui Tang, R. Sridhara, Patricia Keegan, Richard Pazdur, Robert C. Doebele, Dickran Kazandjian,

Colorectal Cancer Treatments and Studies

Response Evaluation Criteria in Solid Tumors (RECIST) permits rapid evaluation of new therapeutic strategies in cancer. However, RECIST does not capture the heterogeneity of response in highly active therapies. Depth of tumor response may provide a more granular view of response. We explored the association between, depth of response (DepOR), with overall survival (OS) and progression-free survival (PFS) for patients with NSCLC being treated with an ALK inhibitor (ALKi) or an anti-PD-1 antibody (Ab).